NPM1 and acute myeloid leukemia: In this sense, the new European LeukemiaNet recommendations [27] for the diagnosis and management of AML in adults now considers all FLT3–ITD-mutated cases (including NPM1 cases with low FLT3–ITD ARs) within the intermediate-risk group and, therefore, candidates for allo-HSCT.